Aquablation therapy for symptomatic benign prostatic hyperplasia: a single‐centre experience in 47 patients
- 10 January 2018
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 121 (6) , 945-951
Abstract
Objective: To report procedure process improvements and confirm the preserved safety and short‐term effectiveness of a second‐generation Aquablation device for the treatment of lower urinary tract symptoms ( LUTS ) attributable to benign prostatic hyperplasia ( BPH ) in 47 consecutive patients at a single institution. Patients and Methods: Aquablation was performed in 47 patients with symptomatic BPH at a single institution. Baseline, peri‐operative and 3‐month urinary function data were collected. Results: The mean (range) patient age was 66 (50–79) years, and transrectal ultrasonography‐measured prostate volume was 48 (20–118) mL. A median lobe was present in 25 patients (53%) and eight patients had catheter‐dependent urinary retention. The mean (range) total procedure time was 35 (13–128) min and the tissue resection time was 4 (1–10) min. Five Clavien–Dindo grade I/ II and five Clavien–Dindo grade III complications were recorded in eight patients. The mean (range) hospital stay was 3.1 (1–8) days and the mean (range) duration of urethral catheterization was 1.9 (1–11) days. The mean International Prostate Symptom Score ( IPSS ) decreased from 24.4 at baseline to 5 at 3 months; IPSS quality‐of‐life score decreased from 4.5 to 0.3 points; peak urinary flow rate increased from 7.1 to 16.5 mL/s and post‐void residual urine volume decreased from 119 to 43 mL (all P < 0.01). Conclusions: This study confirmed procedure process improvements resulting from system enhancements, with preservation of safety and effectiveness during use of a second‐generation device for the treatment of LUTS attibutable to BPH in the largest single‐institution study conducted to date.Keywords
Funding Information
- PROCEPT BioRobotics
This publication has 10 references indexed in Scilit:
- Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: 1-Year ResultsJournal of Urology, 2017
- Multicenter international experience of 532 nm-laser photo-vaporization with Greenlight XPS in men with large prostates (prostate volume > 100 cc)World Journal of Urology, 2017
- Aquablation – image‐guided robot‐assisted waterjet ablation of the prostate: initial clinical experienceBJU International, 2015
- Image-Guided Robot-Assisted Prostate Ablation Using Water Jet-Hydrodissection: Initial Study of a Novel Technology for Benign Prostatic HyperplasiaJournal of Endourology, 2015
- 180-W XPS GreenLight Laser Vaporisation Versus Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 6-Month Safety and Efficacy Results of a European Multicentre Randomised Trial—The GOLIATH StudyEuropean Urology, 2014
- The modified Clavien classification system: a standardized platform for reporting complications in transurethral resection of the prostateWorld Journal of Urology, 2010
- Transurethral Resection of the ProstateEuropean Urology Supplements, 2009
- Validity study of the severity index, a simple measure of urinary incontinence in womenBMJ, 2001
- Factors influencing morbidity in patients undergoing transurethral resection of the prostateUrology, 1999
- The American Urological Association Symptom Index for Benign Prostatic HyperplasiaJournal of Urology, 1992